Pfizer’s Hympavzi receives European approval to treat adults and adolescents with haemophilia A or B with inhibitors: New York Pfizer Inc ...
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
Study demonstrates superiority, showing both statistically significant and clinically meaningful reduction in annualized bleeding rate with a generally well-tolerated safety profile compared to ...
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the ...
Pfizer Inc. (NYSE: PFE)today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for ...
Hantavirus pulmonary infection is a disease caused by some hantaviruses, not the Pfizer-BioNTech COVID-19 vaccine, contrary ...
An oral drug from Pfizer causes a similar amount of weight loss as the blockbuster Ozempic injection, made by rival Novo Nordisk, according to results from a phase two clinical trial. The results were ...
The decisions by Pfizer and Merck to share their COVID-19 drug patents stands in stark contrast to the refusal of Pfizer and other vaccine-makers to release their vaccine recipes ...
(RTTNews) - Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results